New york heart association class versus amino-terminal pro-B type natriuretic peptide for acute heart failure prognosis

Biomarkers

Volumn 15, Issue 4, 2010, Pages 307-314

  Baggish, Aaron L ^a   Van Kimmenade, Roland R J ^b   Pinto, Yigal ^b   Richards, A Mark ^c   Lainchbury, John ^c   Bayes Genis, Antoni ^d   Santaló, Miquel ^d   Ordonez Llanos, Jordi ^d   Januzzi, James L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Acute decompensated heart failure; Natriuretic peptides; NT proBNP; NYHA; Prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; TROPONIN T;

ACUTE HEART FAILURE; AGED; ARTICLE; BODY MASS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MORTALITY; PHYSICAL EXAMINATION; PROGNOSIS; PROTEIN BLOOD LEVEL; SINUS RHYTHM; SURVIVAL RATE; SYSTOLIC HEART FAILURE; THORAX RADIOGRAPHY;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NEW YORK; PATIENT SELECTION; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; VENTRICULAR FUNCTION, LEFT;

EID: 77952530946     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/13547501003632580     Document Type: Article

References (28)

1. Ahmed A, Aronow WS, Fleg JL. (2006). Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function. Am Heart J 151:444-50.
2. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH. (2005). Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352:225-37.
3. Bayes-Genis A, Santalo-Bel M, Zapico-Muniz E, Lopez L, Cotes C, Bellido J, Leta R, Casan P, Ordonez-Llanos J. (2004). N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur J Heart Fail 6:301-8.
4. Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek B, Pacher R. (2002). B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 105:2392-7.
5. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. (2005). The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352:1539-49. (Pubitemid 40517094)
6. Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ. (2005). Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 293:572-80.
7. Forrester JS, Diamond GA, Swan HJ. (1977). Correlative classification of clinical and hemodynamic function after acute myocardial infarction. Am J Cardiol 39:137-45.
8. HFSA. (2006). Executive summary: HFSA.2006 Comprehensive Heart Failure Practice Guideline. J Card Fail 12:10-38.
9. Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, Tung R, Cameron R, Nagurney JT, Chae CU, Lloyd-Jones DM, Brown DF, Foran-Melanson S, Sluss PM, Lee-Lewandrowski E, Lewandrowski KB. (2005). The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95:948-54.
10. Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, Pinto YM, Richards M. (2006). NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 27:330-7.
11. Killip T 3rd, Kimball JT. (1967). Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 20:457-64.
12. Lainchbury JG, Campbell E, Frampton CM, Yandle TG, Nicholls MG, Richards AM. (2003). Brain natriuretic peptide and N-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 42:728-35.
13. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. (1999). A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130:461-70.
14. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, Maggioni A, Burton P, Sullivan MD, Pitt B, Poole-Wilson PA, Mann DL, Packer M. (2006). The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 113:1424-33.
15. Maisel A. (2002). B-type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure: what's next? Circulation 105:2328-31. (Pubitemid 34556380)
16. Maisel A, Hollander JE, Guss D, McCullough P, Nowak R, Green G, Saltzberg M, Ellison SR, Bhalla MA, Bhalla V, Clopton P, Jesse R. (2004). Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 44:1328-33.
17. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA. (2002). Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347:161-7.
18. Maron BJ, Tolakanahalli VN, Zenovich AG, Casey SA, Duprez D, Aeppli DM, Cohn JN. (2004). Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation 109:984-9.
19. Miller WL, Hartman KA, Burritt MF, Grill DE, Rodeheffer RJ, Burnett JC Jr, Jaffe AS. (2007). Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time. Circulation 116:249-57.
20. Muntwyler J, Abetel G, Gruner C, Follath F. (2002). One-year mortality among unselected outpatients with heart failure. Eur Heart J 23:1861-6.
21. Nohria A, Tsang SW, Fang JC, Lewis EF, Jarcho JA, Mudge GH, Stevenson LW. (2003). Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 41:1797-804.
22. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. (2006). Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355:251-9.
23. Pfister R, Scholz M, Wielckens K, Erdmann E, Schneider CA. (2004). Use of NT-proBNP in routine testing and comparison to BNP. Eur J Heart Fail 6:289-93.
24. Radford MJ, Arnold JM, Bennett SJ, Cinquegrani MP, Cleland JG, Havranek EP, Heidenreich PA, Rutherford JD, Spertus JA, Stevenson LW, Goff DC, Grover FL, Malenka DJ, Peterson ED, Redberg R F. (2005). ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Heart Failure Clinical Data Standards): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Failure Society of America. Circulation 112:1888-916.
25. Scrutinio D, Lagioia R, Ricci A, Clemente M, Boni L, Rizzon P. (1994). Prediction of mortality in mild to moderately symptomatic patients with left ventricular dysfunction. The role of the New York Heart Association classification, cardiopulmonary exercise testing, two-dimensional echocardiography and Holter monitoring. Eur Heart J 15:1089-95.
26. Senni M, Santilli G, Parrella P, De Maria R, Alari G, Berzuini C, Scuri M, Filippi A, Migliori M, Minetti B, Ferrazzi P, Gavazzi A. (2006). A novel prognostic index to determine the impact of cardiac conditions and co-morbidities on one-year outcome in patients with heart failure. Am J Cardiol 98:1076-82.
27. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. (2006). Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 47:76-84.
28. Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, Granger CB, Hradec J, Kuch J, McKelvie RS, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Held P, Solomon SD, Yusuf S, Swedberg K. (2004). Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 110:2618-26.